CARE Pharmacies, Leading Edge Pharms expand access to opioid alternatives for pain

Print Friendly, PDF & Email

HENDERSON, Nev. — CARE Pharmacies Cooperative Inc. (CARE), a growing independent retail drug chain serving local communities throughout the United States, and Leading Edge Pharms, Inc. (Leading Edge), a biotechnology company developing novel cannabinoid therapies and innovative delivery platforms, announced today a preferred provider relationship for Leading Edge to provide Cannavera Topical Pain Relief products to CARE pharmacies member pharmacies.

“CARE Pharmacies has been a trusted source of medications for over 60 years. Our new partnership with Leading Edge demonstrates our unwavering commitment to delivering better medicine to more people,” said Mark Ey, vice president of operations for CARE Pharmacies. “Leading Edge’s Cannavera Topical Pain Relief series can be an effective and natural first step in pain management. We are proud to offer these products to our member pharmacies, which can significantly improve the quality of life of those managing chronic pain.”

Through this preferred relationship, CARE Pharmacies will offer Cannavera products at over 100 locations in 22 states to patients from hospitals, physical rehabilitation centers and pain clinics. All Cannavera products are manufactured at an FDA-registered laboratory and follow current Good Manufacturing Practices (cGMP). 

“This new partnership provides Cannavera consumers with a simple, secure and convenient purchase option,” said David Chadwick, chief executive officer of Leading Edge Pharms. “We share a mutual commitment with CARE Pharmacies: providing quality non-opioid solutions for pain management. We strive to provide the very best cannabinoid therapies through innovative delivery systems that are natural, safe and effective in order to address the unacceptable harmful side-effects attributed to the use of opioid drugs. Our partnership with CARE will play an important role in helping us achieve that vision.”



Comments are closed.